Text Size

Comparative Study of Latanoprost Drug Delivery Systems for Glaucoma Treatment and Their Interaction with the Tear Film Lipid Layer Models

Saija M.C.; Vazdar K.; Pajerski W.; Olżyńska A.; Daull P.; Garrigue J.-S.; Cwiklik L.


  • 2023
  • Molecular Pharmaceutics
View publication
  • Therapeutic Area

    Glaucoma

  • Technology

    Drug Delivery

  • Affiliations

    J. Heyrovský Institute of Physical Chemistry, Czech Academy of Sciences, Dolejškova 3, Prague, 18223, Czech Republic; Department of Physical and Macromolecular Chemistry, Faculty of Science, Charles University, Hlavova 8, Prague, 12800, Czech Republic; SANTEN SAS, Novagali Innovation Center, 1 rue Pierre Fontaine, Bâtiment Genavenir IV, Evry, F-91458 Cedex, France

Related Publications

A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Konstas A.G.; Garhöfer G.; Lübke Y.; Voykov B.; Ropo A.


Valproic Acid Application to Modify Post Surgical Fibrosis in a Model of Minimally Invasive Bleb Surgery

Lo P.F.; Gunawan M.; Yap Z.L.; Leong C.; Kwek F.; Varadarajan J.; Wang X.; Kageyama M.; Wong T.T.


The rate of failure of trabeculectomy and tube shunt surgery in eyes with uveitic glaucoma and ocular hypertension: The purpose of this study is to look at the outcomes of trabeculectomy and tube shunt surgery in a large cohort of patients with uveitis

Groth S.L.; Newcomb C.W.; Yang W.; Payal A.; Begum H.; Khachatryan N.; Kaçmaz R.O.; Dreger K.A.; Rosenbaum J.T.; Nida Sen H.; Suhler E.B.; Thorne J.E.; Bhatt N.P.; Foster C.S.; Jabs D.A.; Levy-Clarke G.A.; Buchanich J.M.; Ying G.S.; Kempen J.H.; Gangaputra S.;


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022